Company intelligence / Profile preview

CarthroniX

Lancaster, California, United States

Ownership: Private
Development stage: Other

Overview

CarthroniX has received FDA clearance to begin dosing in a Phase 1/2a trial for its small molecule regenerative medicine CX-011, with additional preclinical programs in fibrosis, hair loss/wound healing, and animal health; early studies show induction of repair and regeneration via gp130 modulation.

Therapeutic areas: OncologyOtherDermatologyRheumatology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

CX-011

1 more asset in the full pipeline.

Request access →

Partnerships

Boehringer Ingelheim (partnered in animal health/canine oncology)Pacira BioSciences (led convertible note financing, potential strategic investor)NIH/NIAMS (SBIR grant recipient for fibrosis program)University of Southern California (USC; academic partner)

Beyond the preview

Go deeper on CarthroniX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CarthroniX.

Explore the full profile